NEW YORK – Janssen this week said its CAR T-cell therapy, ciltacabtagene autoleucel (cilta-cel), will undergo accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) as a
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.